Show simple item record

dc.contributor.authorAlnıgenis, M. Nergis
dc.date.accessioned2016-06-10T13:31:33Z
dc.date.available2016-06-10T13:31:33Z
dc.date.issued2000
dc.identifier.urihttp://hdl.handle.net/11424/4655
dc.description.abstractRheumatoid Factor (RF) is the only serologic marker used in the diagnosis of rheumatoid arthritis (RA). Since it is present in a number of diseases other than RA and found negative in some patients with RA, diagnostic utility of RF has some limitations. Several more specific autoantibodies detected in the sera of RA patients are not routinely tested. Antiperinuclear factor (APF) and antikeratin antibodies (AKA) are two of these antibodies. In previously reported series, the APF was present in 49% and 87% of RA patients with a specificity between 73% and 99%. AKA was detected positive in 36% to 59% of the RA patients, and its specificity was 88% to 99. In this article, we have reviewed characteristics, significance in the pathogenesis and the diagnostic use of these two antibodies in RA.en_US
dc.language.isoengen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRheumatoid Arthritis, Autoantibodies, Antiperinuclear Factor, Antikeratin antibody.en_US
dc.titleClınıcal sıgnıfıcance of antıperınuclear factor and antıkeratın antıbody for rheumatoıd arthrıtısen_US
dc.typearticleen_US
dc.relation.journalMarmara Medicial Journalen_US
dc.contributor.departmentDivision of Rheumatology, Montefiore Medical Center, Albert Einstein College of Medicine, new York, USAen_US
dc.identifier.volume13en_US
dc.identifier.issue3en_US
dc.identifier.startpage169en_US
dc.identifier.endpage175en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record